CV Therapeutics presents novel fatty acid oxidation inhibitors for cardiovascular disorders Oct. 21, 2002
Phase III trial evaluates E2F Decoy for prevention of coronary artery bypass graft failure Oct. 16, 2002
Celera Diagnostics and Bristol-Myers Squibb collaborate on cardiovascular disease and diabetes Oct. 15, 2002
RSS